Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis

被引：0

作者：

Hansen, Karen E. ^{[1
]}

Mortezavi, Mahta ^{[2
]}

Nagy, Edward ^{[3
]}

Wang, Cunshan ^{[4
]}

Connell, Carol A. ^{[4
]}

Radi, Zaher ^{[5
]}

Litman, Heather J. ^{[6
]}

Adami, Giovanni ^{[7
]}

Rossini, Maurizio ^{[7
]}

机构：

[1] Univ Wisconsin, Rheumatol Div, Dept Med, Sch Med & Publ Hlth, Madison, WI USA

[2] Pfizer Inc, New York, NY USA

[3] Pfizer Ltd, Tadworth, England

[4] Pfizer Inc, Groton, CT USA

[5] Pfizer Inc, Cambridge, MA USA

[6] CorEvitas LLC, Waltham, MA USA

[7] Univ Verona, Dept Med, Rheumatol Unit, Verona, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1431

引用

页码：2821 / 2824

页数：4

共 4 条

[1] JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function
Adam, Susanne
Simon, Nils
Steffen, Ulrike
Andes, Fabian T.
Scholtysek, Carina
Mueller, Dorothea I. H.
Weidner, Daniela
Andreev, Darja
Kleyer, Arnd
Culemann, Stephan
Hahn, Madelaine
Schett, Georg
Kroenke, Gerhard
Frey, Silke
Hueber, Axel J.
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (530)
[2] FRAX™ and the assessment of fracture probability in men and women from the UK
Kanis, J. A.
Johnell, O.
Oden, A.
Johansson, H.
McCloskey, E.
[J]. OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) : 385 - 397
[3] Kremer, 2021, ACR OPEN RHEUMATOL, V3, P173
[4] Ytterberg SR, 2022, NEW ENGL J MED, V386, P316, DOI [10.1056/NEJMoa2109927, 10.1056/NEJMc2202778]